|
||
“Our Feel-Good War on Breast Cancer: MBCN Responds.” By Katherine O’Brien, MBCN Secretary, Metastatic Breast Cancer Network. Editor’s Note: Peggy Orenstein’s April 25, 2013 article–the cover story for this Sunday’ s New York Times’ Magazine, demonstrates a remarkable depth and thoughtfulness. It is long–but well-worth the effort to read. For those looking for a quick . . . → Read More: Our Feel-Good War on Breast Cancer: MBCN Responds 
Assessing the ‘Pink Ribbon’ Campaign (audio, 51:58 min.) In recent years, cancer specialists have warned that aggressive early screening for people at low risk for breast cancer may do more harm than good because it can lead to unnecessary treatment. Yet expensive awareness campaigns — featuring those ubiquitous pink ribbons — continue to . . . → Read More: Assessing the ‘Pink Ribbon’ Campaign 
This is how things change. On Tuesday, April 9 we celebrate DH’s (darling husband’s) birthday with an extravagant dinner with friends at our favorite restaurant. We make happy noises about the food and pass around bites so rich it is absurd to even contemplate their arterial impact. We simply go with the moment and . . . → Read More: Cancer: Round Two 
“Our Feel-Good War on Breast Cancer.” By Peggy Orenstein, The New York Times Magazine. I used to believe that a mammogram saved my life. I even wrote that in the pages of this magazine. It was 1996, and I had just turned 35 when my doctor sent me for an initial screening — a . . . → Read More: Our Feel-Good War on Breast Cancer 
“What a peaceful death.” This is what the head nurse in the isolation unit remarked upon entering my father’s hospital room shortly after he died. The room was quiet, to be sure, but it had not been a peaceful departure. I know this for a fact. I was there. Still, throughout the early morning, as . . . → Read More: The Making of a Peaceful Death 
When the Human Genome Project started in 1990 there were fewer than 100 genes associated with human diseases. The first genetic mutation (for Huntington’s disease) was identified in 1986, just a few years before the Project started. After more than a decade of technological innovation and about $3.8 billion, a team of scientists across more . . . → Read More: Patients, Patents, and Profits in a Genomic Age
“States Take Drug Makers to Court Over Marketing.” By Peter Loftus, Wall Street Journal. Authorities in some U.S. states have become more aggressive in accusing drug makers of deceptive marketing, widening the potential liability for an industry that has shelled out billions of dollars to settle investigations led by the federal government. A key legal . . . → Read More: States Take Drug Makers to Court Over Marketing 
The summer before Jennifer died we spent a week at the ocean with her family. At this point Jen had been using a walker for a few months because the cancer had spread to her hip and she was having difficultly walking. Jen’s legs were getting weaker and she wasn’t sure that she would be . . . → Read More: “Topsail” – New Video from Angelo Merendino 
In a 2012 Breast Cancer Consortium research brief, we highlighted an article in the “not so” column of the British Medical Journal (published August 12th). The column is an occasional series highlighting the exaggerations, distortions, and selective reporting that make some news stories, advertising, and medical journal articles. In it, professors Lisa M. Schwartz MD . . . → Read More: Follow-up: Susan G. Komen [for the Cure] Still Overselling Mammography
“Are Pricey Computer-Aided Mammograms Worth It?” By Christine Norton and Karen Sepucha, Health News Review). Health News Review evaluates health reporting on medical interventions from the top ten circulating newspapers in the United States. The evaluation is based on established criteria related to costs of the intervention, quantification of benefits and harms, critical evaluation of . . . → Read More: Are Pricey Computer-Aided Mammograms Worth It? |
||
| Copyright © 2026 Breast Cancer Consortium – Archives - All Rights Reserved. Privacy Policy | ||